FMP
CRISPR Therapeutics AG
CRSP
NASDAQ
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
42.12 USD
0.13 (0.309%)
2024
2023
2022
2021
-142.77M
-260.38M
-495.74M
538.97M
-366.25M
-153.61M
-650.17M
377.66M
19.26M
19.84M
24.17M
17.95M
0
0
0
0
86.57M
81.03M
97.95M
102.39M
156.27M
-193.59M
19.84M
26.86M
175M
-200M
305k
-161k
0
23.33M
0
-37.51M
0
-20.25M
5.16M
37.51M
-18.73M
3.33M
14.38M
27.02M
-38.62M
-14.04M
12.47M
14.11M
-280.48M
374.65M
-258.65M
-1.04B
-1.9M
-9.47M
-37.19M
-81.7M
0
0
221.47M
953.73M
-1.46B
-1.07B
-1.42B
-1.51B
1.21B
1.45B
1.2B
555.6M
-23.18M
-2.5M
-221.47M
-953.73M
331.98M
62.66M
38.59M
250.94M
0
0
0
0
300.69M
32.72M
970k
213.27M
0
0
0
0
0
0
0
0
31.29M
29.94M
37.62M
37.68M
-144.68M
-272.35M
-532.93M
457.27M
-142.77M
-260.38M
-495.74M
538.97M
-1.9M
-11.97M
-37.19M
-81.7M
401.07M
224.06M
939.94M
1.19B
309.78M
401.07M
224.06M
939.94M
-91.29M
177.01M
-715.88M
-245.52M
2024
2023
2022
2021
-999.7M
-846.09M
-195.91M
-573.58M
-366.25M
-153.61M
-650.17M
377.66M
0
0
0
0
0
0
0
0
-1.37B
-999.7M
-846.09M
-195.91M
-366.25M
-153.61M
-650.17M
377.66M
2024
2023
2022
2021
277.55M
305.94M
320.56M
312.04M
0
19.84M
24.17M
17.95M
-1.9M
-11.97M
-37.19M
-81.7M
279.45M
298.07M
333.57M
375.79M
2024
2023
2022
2021
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.